PubMed Health⌕ Search

Biomedical subjects

T F Rose

Publications and source records attributed to T F Rose.

10 recordsLinked to original sources
PubMed1990

Plasma and dialysate levels of pefloxacin and its metabolites in CAPD patients with peritonitis.

Six patients with acute peritonitis undergoing continuous ambulatory peritoneal dialysis for end-stage renal failure received an 800 mg loading dose of pefloxacin mesylate orally followed by 400 mg twice daily orally for 10 or 21 days. Plasma and dialysate levels of both pefloxacin and its metabolites were measured. Plasma levels in excess of the MIC for all infective bacteria were achieved within 90 min and in dialysate within 4 h. No significant accumulation of pefloxacin or its metabolite norfloxacin was noted. However, both serum and dialysate levels of the metabolite pefloxacin N-oxide rose continuously during treatment. Plasma and dialysate levels of all three agents fell rapidly during the five days after treatment had stopped. No major side effects were observed, although two patients developed Achilles tendonitis.

Adult↗
PubMed1990

Oral pefloxacin mesylate in the treatment of continuous ambulatory peritoneal dialysis associated peritonitis: an open non-comparative study.

Twenty-two (15 female and 7 male) patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis were entered into an open non-comparative evaluation of oral pefloxacin mesylate. An initial loading dose of 800 mg was followed by 400 mg twice daily. Five patients were subsequently excluded or withdrawn. The mean age of the patients was 44 +/- 12.6 years. All three Gram-negative infections (Escherichia coli, Acinetobacter calcoaceticus, Serratia liquefaciens) and all three culture negative infections were cured after 21 days treatment. In contrast one of four (25%) Staphylococcus aureus infections was cured, two persisted during treatment and one relapsed, after treatments of between 10 and 25 days. One of seven (14%) Staph. epidermidis infections was cured, three persisted and three relapsed after treatments of between nine and 25 days. Two of the five persistent isolates became resistant: all four relapsed isolates remained sensitive. Twelve of the 22 (55%) patients had 16 side effects, most commonly skin or musculo-skeletal. Three stopped pefloxacin because of them, though one had taken an excessive dose in error. Pefloxacin mesylate is not optimal treatment for Gram-positive coccal peritonitis in patients on CAPD, but its role in Gram-negative disease needs further evaluation.

Administration, Oral↗